American Research Corporation at theTexas Liver Institute

San Antonio, Texas 78215

10 studies enrolling now · 43 studies all time

What they study most

Chronic Hepatitis B, Compensated Liver Cirrhosis, Healthy, Hepatic Cirrhosis, Hepatic Encephalopathy (HE), Hepatic Impairment, Hepatic Insufficiency, Hypertension, Hypertension, Portal, Liver Cirrhosis, Liver Cirrhosis, Biliary, Liver Diseases

Studies at this site

• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD — Recruiting now
• A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) — Recruiting now
• A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems — Recruiting now
• A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis — Recruiting now
• A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis — Recruiting now
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Recruiting now
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Recruiting now
• A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems — Recruiting now
• A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. — Running, not enrolling
• Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC — Completed
• A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. — Completed
• Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects — Running, not enrolling
• A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH — Completed
• A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH — Completed
• A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease — Completed
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) — Stopped early
• A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems — Completed
• A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems — Stopped early
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) — Completed
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) — Completed
• A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 — Completed
• A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage — Completed
• Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment — Completed
• Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) — Completed
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH — Stopped early
• Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) — Stopped early
• A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection — Stopped early
• Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment — Stopped early
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) — Completed
• Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 — Withdrawn before enrolling
• MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) — Completed
• A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems — Completed
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis — Completed
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function — Completed
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH — Completed
• Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) — Completed
• A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers — Completed